Lie Deng | Oncology | Outstanding Contribution Award

Mr.  Lie Deng | Oncology | Outstanding Contribution Award

Foshan institution of pathogenic microorganism | China

This academic summary highlights advanced expertise in medical research design, Oncology statistical analysis, biochemical and molecular biology techniques, cell culture methodologies, and bioinformatics, with a strong focus on respiratory syncytial virus research. The work emphasizes the development and optimization of molecular and immunological assays to support vaccine evaluation and translational research. Robust reverse transcription quantitative polymerase chain reaction and antibody enzyme linked immunosorbent assay methods were established to assess viral load and immune responses, providing reliable alternatives to commercially available detection systems while improving laboratory efficiency and accessibility. Comprehensive research efforts also include critical analysis of global vaccine development strategies, encompassing diverse technical routes such as live attenuated vaccines, subunit vaccines, vector based platforms, and nucleic acid approaches. These contributions integrate experimental data with comparative evaluation frameworks, offering valuable insights into vaccine design, efficacy assessment, and methodological standardization. In addition, the preparation of detailed molecular biology operation guidelines strengthened laboratory practices and ensured reproducibility of experimental workflows. Training activities focused on molecular cloning, polymerase chain reaction based assays, and data validation principles, supporting the development of independent experimental competence and high quality data generation. Overall, this body of work demonstrates a strong integration of experimental innovation, methodological rigor, and knowledge dissemination, contributing meaningfully to vaccine research, laboratory capacity building, and the advancement of evidence based evaluation methods in virology and immunological studies.

Profile: ORCID

Featured Publications 

Deng, L., Cao, H., Li, G., Zhou, K., Fu, Z., Zhong, J., Wang, Z., & Yang, X. (2025). Progress on respiratory syncytial virus vaccine development and evaluation methods. Vaccines, 13(3), 304.

Assoc Prof Dr. S. Mohsen Asghari – Cancer diagnosis – Best Innovation Award

Assoc Prof Dr. S. Mohsen Asghari - Cancer diagnosis - Best Innovation Award

University of Tehran - Iran

Professional Profile

ORCID

EARLY ACADEMIC PURSUITS 🎓

S. Mohsen Asghari was born in 1978 and embarked on his academic journey at Gorgan University, Iran, where he earned his B.Sc. in Biology in 2000. He pursued further studies at Tarbiat Modares University, Tehran, completing his M.Sc. in Biochemistry in 2003 and his Ph.D. in 2008. His doctoral research included a significant stint at Utrecht University in the Netherlands, where he honed his expertise in protein engineering.

PROFESSIONAL ENDEAVORS 🏛️

Following his Ph.D., Dr. Asghari joined the University of Guilan in 2009 as an assistant professor, ascending to the role of associate professor in 2017. His academic career took a pivotal turn in 2020 when he joined the Institute of Biochemistry and Biophysics at the University of Tehran. Here, he has been instrumental in advancing research and teaching in the field of novel anticancer peptides. Dr. Asghari’s professional role extends beyond academia as he leads a knowledge-enterprise company focused on peptide-based industrial applications.

CONTRIBUTIONS AND RESEARCH FOCUS 🔬

Dr. Asghari’s research is centered around developing novel peptides and peptidomimetics with potential medical applications. His work includes VEGF-mimicking peptides that interact with key tumor microenvironment receptors and endostatin-derived peptides that inhibit angiogenesis. These peptides are designed to enhance tumor imaging, targeted drug delivery, and the inhibition of pathological angiogenesis, providing Cancer diagnosis innovative solutions for cancer and age-related diseases. His ongoing projects include developing peptide-based technologies for tumor imaging and drug delivery, with a focus on improving therapeutic outcomes and diagnostic precision.

ACCREDITATIONS AND RECOGNITION 🏆

Dr. Asghari holds a US patent for a method of synthesizing antagonist peptides and has published over 80 articles on tumor-targeting peptides. His contributions have been recognized through various awards and fellowships, including the European Association for Cancer Research (EACR) travel fellowship and several industry grants. His editorial roles as Associate Editor for the Iranian Journal of Science and Topic Editor for Cancer diagnosis Frontiers in Oncology further highlight his esteemed position in the scientific community.

IMPACT AND INFLUENCE 🌍

Dr. Asghari’s innovative approach has had a profound impact on cancer research and peptide technology. His work has led to significant advancements in tumor imaging and targeted therapy, influencing both academic research and practical applications. The peptide-based growth supplement for aquaculture developed under his leadership demonstrates his commitment to translating scientific discoveries into real-world Cancer diagnosis solutions, enhancing food security and productivity in Iran.

LEGACY AND FUTURE CONTRIBUTIONS 🔮

Dr. Asghari’s legacy is defined by his pioneering work in peptide science and his contributions to cancer therapy and imaging. His innovative research continues to push the boundaries of biochemistry and biophysics, with ongoing projects aimed at expanding the applications of peptide technology. His role as CEO of a knowledge-enterprise company underscores his dedication to integrating scientific research with industrial practice, promising continued advancements and practical benefits in the future.

NOTABLE PUBLICATIONS